Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma

Steffi E. M. van de Ven, Lucia Suzuki, Annieke W. Gotink, Fiebo J. C. ten Kate, Daan Nieboer, Bas L. A. M. Weusten, Lodewijk A. A. Brosens, Richard van Hillegersberg, Lorenza Alvarez Herrero, Cees A. Seldenrijk, Alaa Alkhalaf, Freek C. P. Moll, Wouter Curvers, Ineke G. van Lijnschoten, Thjon J. Tang, Hans van der Valk, Wouter B. Nagengast, Gursah Kats-Ugurlu, John T. M. Plukker, Martin H. M. G. HoubenJaap S. van der Laan, Roos E. Pouw, Jacques J. G. H. M. Bergman, Sybren L. Meijer, Mark I. van Berge Henegouwen, Bas P. L. Wijnhoven, Pieter J. F. de Jonge, Michael Doukas, Marco J. Bruno, Katharina Biermann, Arjun D. Koch*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Aim: To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma. Methods: In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinoma. Primary endpoint was the presence of metastases, lymph node metastases, or distant metastases, in surgical resection specimens or during follow-up. A prediction model to identify risk factors for metastases was developed and internally validated. Results: 248 patients were included. LVI was distributed as follows: no LVI (n = 196; 79.0%), 1 LVI focus (n = 16; 6.5%), 2–3 LVI foci (n = 21; 8.5%) and ≥4 LVI foci (n = 15; 6.0%). Seventy-eight patients had metastases. The risk of metastases was increased for tumors with 2–3 LVI foci [subdistribution hazard ratio (SHR) 3.39, 95% confidence interval (CI) 2.10–5.47] and ≥4 LVI foci (SHR 3.81, 95% CI 2.37–6.10). The prediction model demonstrated a good discriminative ability (c-statistic 0.81). Conclusion: The risk of metastases is higher when more LVI foci are present. Quantification of LVI could be useful for a more precise risk estimation of metastases. This model needs to be externally validated before implementation into clinical practice.
Original languageEnglish
Pages (from-to)1066-1073
Number of pages8
JournalUnited European Gastroenterology Journal
Issue number9
Early online date2021
Publication statusPublished - Nov 2021

Cite this